Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.56 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.56 |
| ▸ | MGAM | O43451 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | SI | P14410 | 5/20 | 0.56 |
| ▸ | MGAM2 | Q2M2H8 | 5/20 | 0.56 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.50 |
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | MPL | P40238 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30494622 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10HPGDPIM1 | |
| SCHEMBL23631826 | 0.80 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10HPGDPIM1 | |
| SCHEMBL28051097 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10HPGDPIM1 | |
| SCHEMBL2359695 | 0.79 | ALDH1A1 (0.66) | KDM4EALDH1A1HSD17B10HPGDPIM1 | |
| SCHEMBL30494574 | 0.79 | ALDH1A1 (0.66) | KDM4EALDH1A1HSD17B10HPGDPIM1 | |
| SCHEMBL31536902 | 0.78 | ALDH1A1 (0.65) | KDM4EALDH1A1HSD17B10HPGDMGAM | |
| SCHEMBL11332564 | 0.78 | ALDH1A1 (0.65) | KDM4EALDH1A1HSD17B10HPGDMGAM | |
| SCHEMBL11331284 | 0.78 | MGAM (0.67) | KDM4EALDH1A1HSD17B10HPGDMGAM | |
| SCHEMBL11326692 | 0.78 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10HPGDMGAM | |
| SCHEMBL28353369 | 0.78 | ALDH1A1 (0.65) | KDM4EALDH1A1HSD17B10HPGDMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112279845-B | Aryl or heteroaryl substituted thiadiazoles compounds and antibacterial application thereof | 中国医学科学院药物研究所 | 2023-07-28 | — | — | CN | disclosed |
| CN-112920181-A | N- (5-phenyl-1, 3, 4-thiadiazole-2-yl) benzamide compound | 中国医科大学 | 2021-06-08 | — | — | CN | disclosed |
| EP-3212644-B1 | DERIVATIVES OF 2-(1,2,4-TRIAZOL-3-YLSULFANYL)-N-1,3,4-THIADIAZOL-2-YL ACETAMIDE WHICH ARE USEFUL FOR THE TREATMENT OF DIABETES | APOGLYX AB (SE) | 2021-05-05 | — | — | EP | disclosed |
| EP-3212644-B1 | DERIVATIVES OF 2-(1,2,4-TRIAZOL-3-YLSULFANYL)-N-1,3,4-THIADIAZOL-2-YL ACETAMIDE WHICH ARE USEFUL FOR THE TREATMENT OF DIABETES | APOGLYX AB (SE) | 2021-05-05 | — | — | EP | disclosed |
| CN-112279845-A | Aryl or heteroaryl substituted thiadiazole compounds and antibacterial application thereof | 中国医学科学院药物研究所 | 2021-01-29 | — | — | CN | disclosed |
| CN-107001351-B | Derivatives of 2- (1,2, 4-triazol-3-ylsulfanyl) -N-1,3, 4-thiadiazol-2-ylacetamide useful in the treatment of, in particular, diabetes | 阿波格吕克斯有限公司 | 2020-06-05 | — | — | CN | disclosed |
| US-10130633-B2 | Compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-20 | — | — | US | disclosed |
| US-10011597-B2 | Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-N-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes | APOGLYX AB (SE) | 2018-07-03 | — | — | US | disclosed |
| US-10011597-B2 | Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-N-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes | APOGLYX AB (SE) | 2018-07-03 | — | — | US | disclosed |
| US-10011597-B2 | Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-N-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes | APOGLYX AB (SE) | 2018-07-03 | — | — | US | disclosed |
| US-20160263122-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| WO-2016066696-A1 | DERIVATIVES OF 2-(1,2,4-TRIAZOL-3-YLSULFANYL)-N-1,3,4-THIADIAZOL-2-YL ACETAMIDE WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA DIABETES | APOGLYX AB (SE) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016066696-A1 | DERIVATIVES OF 2-(1,2,4-TRIAZOL-3-YLSULFANYL)-N-1,3,4-THIADIAZOL-2-YL ACETAMIDE WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA DIABETES | APOGLYX AB (SE) | 2016-05-06 | — | — | WO | disclosed |
| EP-2976327-A2 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | disclosed |
| CN-105228982-A | 3-acetylamino-1- (phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino) benzene derivatives for the treatment of hyperproliferative disorders | Bayer Pharma AG | 2016-01-06 | — | — | CN | disclosed |
| WO-2014147021-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
| EP-0453846-A2 | Aryloxycarbonyl compounds | BAYER AG (DE) | 1991-10-30 | — | — | EP | disclosed |
| EP-0005783-B1 | IMIDAZO (2.1-B)-(1.3.4)-THIADIAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICAMENTS | BAYER AG (DE) | 1981-12-30 | — | — | EP | disclosed |
| US-4265898-A | ANTICOAGULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-05 | — | — | US | disclosed |
| EP-0005783-A1 | Imidazo (2.1-b)-(1.3.4)-thiadiazoles, process for their preparation and their use in medicaments | BAYER AG (DE) | 1979-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263122-A1 | NOVEL COMPOUNDS | NAT1, AADAC, CBR3 | KDM4E 2232/4885ALDH1A1 264/4885HSD17B10 805/4885 |
| US-10130633-B2 | Compounds | AADAC, NAT1, CBR3 | KDM4E 2327/4885ALDH1A1 277/4885HSD17B10 1262/4885 |
| US-10011597-B2 | Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-N-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes | AQP1, AQP3, AQP4 | KDM4E 4747/4885ALDH1A1 1327/4885HSD17B10 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.